Group 1 - The company, Huazhong Biopharmaceutical-B (02396.HK), plans to globally offer 17.6488 million H-shares, with 1.765 million shares available in Hong Kong and 15.8838 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The subscription period for the shares is from December 12 to December 17, 2025, with the expected pricing date on December 18, 2025, and trading on the Hong Kong Stock Exchange expected to commence on December 22, 2025 [1] - The company focuses on developing protein drugs for various therapeutic areas, particularly in wound healing therapies, with two core products in its pipeline: Pro-101-1 for deep second-degree burns and Pro-101-2 for diabetic foot ulcers [1] Group 2 - Assuming no exercise of the over-allotment option and a median offer price of HKD 44.60 per share, the company estimates net proceeds from the global offering to be approximately HKD 708.8 million [2] - Approximately 61.8% of the proceeds will be used to fund the ongoing clinical development and commercialization of core products Pro-101-1 and Pro-101-2 [2] - About 18.8% of the proceeds will be allocated to enhance the company's R&D capabilities through the purchase of professional equipment and instruments related to R&D and quality control [2]
华芢生物-B(02396.HK)拟全球发售1764.88万股H股 预计12月22日上市
Ge Long Hui·2025-12-11 23:26